Welcome!

News Feed Item

Migraine Global Clinical Trials Review, H2, 2013

NEW YORK, Oct. 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Migraine Global Clinical Trials Review, H2, 2013
http://www.reportlinker.com/p0681715/Migraine-Global-Clinical-Trials-Review-H2-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Migraine Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, "Migraine Global Clinical Trials Review, H2, 2013" provides data on the Migraine clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Migraine. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Migraine. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Migraine 6
Report Guidance 6

Clinical Trials by Region 7
Clinical Trials by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by BRIC Nations 15
Clinical Trials by G7 Nations 16
Clinical Trials in G7 Nations by Trial Status 17
Clinical Trials by E7 Nations 18
Clinical Trials in E7 Nations by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Migraine 23
Subjects Recruited Over a Period of Time 27
Prominent Sponsors 28
Top Companies Participating in Migraine Therapeutics Clinical Trials 30
Prominent Drug Comparison 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33

Merck & Co., Inc. 33
Clinical Trial Overview of Merck & Co., Inc. 33
GlaxoSmithKline plc 36
Clinical Trial Overview of GlaxoSmithKline plc 36
Johnson & Johnson 39
Clinical Trial Overview of Johnson & Johnson 39
Allergan, Inc. 42
Clinical Trial Overview of Allergan, Inc. 42
AstraZeneca PLC 44
Clinical Trial Overview of AstraZeneca PLC 44
Pfizer Inc. 46
Clinical Trial Overview of Pfizer Inc. 46
Banyan Group, Inc. 48
Clinical Trial Overview of Banyan Group, Inc. 48
NuPathe Inc. 49
Clinical Trial Overview of NuPathe Inc. 49
Endo Health Solutions Inc. 50
Clinical Trial Overview of Endo Health Solutions Inc. 50

Alexza Pharmaceuticals, Inc. 51
Clinical Trial Overview of Alexza Pharmaceuticals, Inc. 51
Clinical Trial Overview of Top Institutes / Government 52
Danish Headache Center 52
Clinical Trial Overview of Danish Headache Center 52
Thomas Jefferson University 54
Clinical Trial Overview of Thomas Jefferson University 54
Montefiore Medical Center 55
Clinical Trial Overview of Montefiore Medical Center 55
Johns Hopkins University 56
Clinical Trial Overview of Johns Hopkins University 56
The Cleveland Clinic 57
Clinical Trial Overview of The Cleveland Clinic 57
Chengdu University of Traditional Chinese Medicine 58
Clinical Trial Overview of Chengdu University of Traditional Chinese Medicine 58
University of Pittsburgh 59
Clinical Trial Overview of University of Pittsburgh 59
Glostrup University Hospital 60
Clinical Trial Overview of Glostrup University Hospital 60
Shahid Beheshti University 61
Clinical Trial Overview of Shahid Beheshti University 61
Swedish Medical Center 62
Clinical Trial Overview of Swedish Medical Center 62

Five Key Clinical Profiles 63
Appendix 109
Abbreviations 109
Definitions 109
Research Methodology 110
Secondary Research 110
About GlobalData 111
Contact Us 111
Disclaimer 111
Source 112


List of Tables
Migraine Therapeutics Market, Global, Clinical Trials by Zone, 2013* 7
Migraine Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Migraine Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Migraine Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 10
Migraine Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 11
Migraine Therapeutics Clinical Trials, North America, Top Countries, 2013* 12
Migraine Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2013* 13
Migraine Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2013* 14
Migraine Therapeutics Clinical Trials, BRIC Countries, 2013* 15
Migraine Therapeutics Clinical Trials, G7 Countries, 2013* 16
Migraine Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Migraine Therapeutics Clinical Trials, E7 Countries, 2013* 18
Migraine Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Migraine Therapeutics Market, Global, Clinical Trials by Phase, 2013* 20
Migraine Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 21

Migraine Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Migraine Therapeutics Market, Global, Suspended Clinical Trials, 2013* 23
Migraine Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 24
Migraine Therapeutics Market, Global, Terminated Clinical Trials, 2013* 25
Migraine Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Migraine Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 29
Migraine Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 31
Migraine Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 32
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2013* 33
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2013* 36
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2013* 39
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2013* 42
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2013* 44
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2013* 46
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Banyan Group, Inc., 2013* 48

Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by NuPathe Inc., 2013* 49
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo Health Solutions Inc., 2013* 50
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Alexza Pharmaceuticals, Inc., 2013* 51
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Danish Headache Center, 2013* 52
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2013* 54
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Montefiore Medical Center, 2013* 55
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2013* 56
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cleveland Clinic, 2013* 57
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Chengdu University of Traditional Chinese Medicine, 2013* 58
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2013* 59
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Glostrup University Hospital, 2013* 60
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Beheshti University, 2013* 61
Migraine Therapeutics Clinical Trials Market, Global, Clinical Trials by Swedish Medical Center, 2013* 62

List of Figures
Migraine Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 7
Migraine Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Migraine Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Migraine Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013* 10
Migraine Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 11
Migraine Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 12
Migraine Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2013* 13
Migraine Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2013* 14
Migraine Therapeutics Clinical Trials, BRIC Countries (%), 2013* 15
Migraine Therapeutics Clinical Trials, G7 Countries (%), 2013* 16
Migraine Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Migraine Therapeutics Clinical Trials, E7 Countries (%), 2013* 18
Migraine Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Migraine Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 20
Migraine Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 21
Migraine Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Migraine Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Migraine Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 28
Migraine Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 30
Migraine Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 32
GlobalData Methodology 110

To order this report: Migraine Global Clinical Trials Review, H2, 2013
http://www.reportlinker.com/p0681715/Migraine-Global-Clinical-Trials-Review-H2-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001

Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at 18th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., will focus on real world deployments of DDoS mitigation strategies in every layer of the network. He will give an overview of methods to prevent these attacks and best practices on how to provide protection in complex cloud platforms. He will also outline what we have found in our experience managing and running thousands of Linux and Unix managed service platforms and what specifically c...
trust and privacy in their ecosystem. Assurance and protection of device identity, secure data encryption and authentication are the key security challenges organizations are trying to address when integrating IoT devices. This holds true for IoT applications in a wide range of industries, for example, healthcare, consumer devices, and manufacturing. In his session at @ThingsExpo, Lancen LaChance, vice president of product management, IoT solutions at GlobalSign, will teach IoT developers how t...
As enterprises around the world struggle with their digital transformation efforts, many are finding that innovative digital teams are moving much faster than their hidebound IT organizations. Rather than struggling to convince traditional IT to get with the digital program, executives are taking advice from IT research firm Gartner, and encouraging existing IT to continue in their desultory ways. However, many CIOs are realizing the dangers of following Gartner’s advice. The central challenge ...
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
A critical component of any IoT project is the back-end systems that capture data from remote IoT devices and structure it in a way to answer useful questions. Traditional data warehouse and analytical systems are mature technologies that can be used to handle large data sets, but they are not well suited to many IoT-scale products and the need for real-time insights. At Fuze, we have developed a backend platform as part of our mobility-oriented cloud service that uses Big Data-based approache...
The pace of innovation, vendor lock-in, production sustainability, cost-effectiveness, and managing risk… In his session at 18th Cloud Expo, Dan Choquette, Founder of RackN, will discuss how CIOs are challenged finding the balance of finding the right tools, technology and operational model that serves the business the best. He will discuss how clouds, open source software and infrastructure solutions have benefits but also drawbacks and how workload and operational portability between vendors...
Cloud Object Storage is effectively infinitely scalable and boasts the lowest total costs. But cloud SLAs and T&Cs are traditionally optimized for huge customers like Netflix, so applications demanding better confidentiality or higher availability typically can’t reap the benefits of public cloud storage. In his session at 18th Cloud Expo, Don Martin, CTO of Security First Corp, will provide an overview of innovative technologies available today – secret sharing and information dispersal algori...
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
As the rapid adoption of containers continues, companies are finding that they lack the operational tools to understand the behavior of applications deployed in these containers, and how to identify issues in their application infrastructure. For example, how are multiple containers within an application impacting each other’s performance? If an application’s service is degraded, which container is to blame? In the case of an application outage, what was the root cause of the outage?
When it comes to IoT in the enterprise, namely the commercial building and hospitality markets, a benefit not getting the attention it deserves is energy efficiency, and IoT's direct impact on a cleaner, greener environment when installed in smart buildings. Until now clean technology was offered piecemeal and led with point solutions that require significant systems integration to orchestrate and deploy. There didn't exist a 'top down' approach that can manage and monitor the way a Smart Buildi...
Cloud-based NCLC (No-code/low code) application builder platforms empower everyone in the organization to quickly build applications and executable processes that broaden access, deepen collaboration, and enhance transparency for all team members. Line of business owners (LOBO) and operations managers know best their part of the business and their processes. IT departments are beginning to leverage NCLC platforms to empower and enable LOBOs to lead the innovation, transform the organization, an...
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...